News

Association Of British Neurologists Releases New Guidelines For Multiple Sclerosis

The Association of British Neurologists (ABN) recently published new guidelines for how Disease Modifying Therapies (DMTs) for relapsing remitting multiple sclerosis should be monitored and prescribed in the United Kingdom, emphasizing the “right treatment at the right time.” There are currently ten DMTs available on the National Health System (NHS) and eleven in…

Canadian Drug Expert Committee Recommends MS Therapy LEMTRADA For Public Coverage

The Canadian Drug Expert Committee (CDEC) recently recommended that LEMTRADA (alemtuzumab) be included in provincial and other public drug plans for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS). The recommendation was made through Canada’s Common Drug Review (CDR) and announced in a press release by the company that…

LMU Researchers Identify Biomarker BCMA to Measure MS Severity

In a recent study published in the journal Nature Communications, LMU clinicians have clarified the lifespan of antibody-producing cells and have also identified a novel biomarker that could be used to monitor autoimmune conditions such as multiple sclerosis and lupus erythematous. The humoral immune response is mediated by cells…

MS Views and News Hosting Events for MS Community in July

MS Views and News (MSVN), a non-profit organization that works to improve education, advocacy and service to empower and enhance the quality of life of patients who suffer from multiple sclerosis (MS), has announced it will offer a series of educational events on different topics throughout the month of July in…

MediciNova Announces Update On Phase 2b Trial of MN-166 (Ibudilast) Involving 255 Progressive MS Patients

MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…

Most MS Survey Respondents Favor Legal Marijuana Access For Medical Use

With 26 states plus the District of Columbia now allowing medical marijuana use, according to a recent North American Research Committee on Multiple Sclerosis (NARCOMS) survey, many people with multiple sclerosis are considering the herb as a therapeutic option. NARCOMS is a research program that allows people with Multiple Sclerosis…

MS Health Care Excellence Awards Launched in UK

UK-based MS Trust has announced the launch of new awards designed to distinguish healthcare professionals that are committed to treating and changing the lives of patients who suffer from multiple sclerosis (MS). The QuDos Awards are currently open for nominations and will feature ten different categories. The QuDoS in MS Awards –…

Novartis Pharma Program Helping Young People with MS Get And Keep Jobs

Most employers these days talk about having workforce diversity oriented policies that support hiring people living with disabilities and chronic diseases, but what distinguishes rhetoric from reality? What in positive, practical terms can companies do in support of helping people living with visible or invisible challenges find and keep gainful…

MS Patient Lifespan, Comorbidities Studied in New Research

Researchers at the University of Manitoba in Canada recently conducted a study that explored the differences in lifespan and comorbidities in patients with multiple sclerosis compared to healthy individuals. The study was recently published in the journal Neurology and is entitled “Effect of comorbidity…

Multiple Sclerosis Community Celebrates World MS Day

World MS Day is celebrated on May 27 as a day dedicated to those who suffer from multiple sclerosis (MS). In order to mark the occasion, organizations, companies, advocates, and communities are hosting events throughout the world to share inspiring stories, raise awareness about the disease and campaign to support both patients…